Literature DB >> 28522081

Natural course and potential prognostic factors for sleep-disordered breathing in multiple system atrophy.

Yasuyoshi Ohshima1, Hideaki Nakayama2, Naho Matsuyama3, Satoshi Hokari3, Takuro Sakagami3, Tomoe Sato4, Toshiyuki Koya3, Tetsuya Takahashi4, Toshiaki Kikuchi3, Masatoyo Nishizawa4, Takayoshi Shimohata4.   

Abstract

OBJECTIVE/
BACKGROUND: Multiple system atrophy (MSA) frequently results in the development of sleep-disordered breathing (SDB). Few reports have described the natural course of this phenomenon. The aim of the present study was to determine the natural course of SDB and prognostic factors associated with such conditions in MSA. PATIENTS/
METHODS: Twenty-four consecutive patients were recruited with probable MSA, who had not been treated with continuous positive airway pressure (CPAP) and had undergone overnight polysomnography (PSG) more than once following the development of snoring or stridor. Based on changes in the apnea-hypopnea index (AHI) over the course of the disease, patients were divided into two groups (AHI-maintained and AHI-deteriorated) and the clinical findings were compared.
RESULTS: Mean duration between the first and last PSG was 2.4 ± 1.5 years, and patients underwent PSG assessment an average of 2.5 ± 0.6 times during this period. During this interval, AHI increased from 19.4 ± 22.8/hour to 34.4 ± 30.1/hour (p = 0.006), although spontaneous improvement was observed in 29% of patients. Following the first PSG, all patients were diagnosed with obstructive sleep apnea; however, the SDB type changed from obstructive sleep apnea to central sleep apnea in 3 of the 24 (13%) patients during the period between the first and last PSG.
CONCLUSIONS: Although SDB associated with MSA exacerbates with disease progression, spontaneous improvement in AHI may occur in some patients. Earlier development of snoring or stridor may predict rapid progression of SDB in MSA.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Multiple system atrophy; Polysomnography; Sleep apnea; Sleep-disordered breathing

Mesh:

Year:  2017        PMID: 28522081     DOI: 10.1016/j.sleep.2017.01.020

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  7 in total

1.  Sleep-Disordered Breathing in Multiple System Atrophy: Pathophysiology and New Insights for Diagnosis and Treatment.

Authors:  Rosalia Silvestri
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

Review 2.  Sleep Abnormalities in MultipleSystem Atrophy.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

3.  Oral appliance therapy for obstructive sleep apnea in multiple system atrophy with floppy epiglottis: a case series of three patients.

Authors:  Toshihiko Mikami; Tadaharu Kobayashi; Daichi Hasebe; Yasuyoshi Ohshima; Tetsuya Takahashi; Takayoshi Shimohata
Journal:  Sleep Breath       Date:  2022-03-29       Impact factor: 2.816

4.  Breathing Irregularity Is Independently Associated With the Severity of Obstructive Sleep Apnea in Patients With Multiple System Atrophy.

Authors:  Hideaki Nakayama; Satoshi Hokari; Yasuyoshi Ohshima; Takayuki Matsuto; Takayoshi Shimohata
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

Review 5.  Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review.

Authors:  Carmen Rodríguez-Blázquez; Maria João Forjaz; Monica M Kurtis; Roberta Balestrino; Pablo Martinez-Martin
Journal:  Front Neurol       Date:  2018-06-07       Impact factor: 4.003

Review 6.  An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention.

Authors:  Viorica Chelban; Daniela Catereniuc; Daniela Aftene; Alexandru Gasnas; Ekawat Vichayanrat; Valeria Iodice; Stanislav Groppa; Henry Houlden
Journal:  J Neurol       Date:  2020-05-20       Impact factor: 4.849

Review 7.  Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.

Authors:  Kurt A Jellinger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.